Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $109.0 million.

  • Allogene Therapeutics' Total Non-Current Liabilities fell 742.44% to $109.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.0 million, marking a year-over-year decrease of 742.44%. This contributed to the annual value of $118.8 million for FY2024, which is 530.6% down from last year.
  • Per Allogene Therapeutics' latest filing, its Total Non-Current Liabilities stood at $109.0 million for Q3 2025, which was down 742.44% from $110.9 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Total Non-Current Liabilities peaked at $152.9 million during Q1 2023, and registered a low of $97.2 million during Q2 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $118.8 million (2024), whereas its average is $122.7 million.
  • Per our database at Business Quant, Allogene Therapeutics' Total Non-Current Liabilities skyrocketed by 4650.08% in 2022 and then plummeted by 2164.83% in 2024.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Total Non-Current Liabilities stood at $117.8 million in 2021, then grew by 26.32% to $148.8 million in 2022, then fell by 15.74% to $125.4 million in 2023, then fell by 5.31% to $118.8 million in 2024, then dropped by 8.25% to $109.0 million in 2025.
  • Its Total Non-Current Liabilities was $109.0 million in Q3 2025, compared to $110.9 million in Q2 2025 and $111.3 million in Q1 2025.